Having talked up its intention to invest in neuroscience R&D, Sanofi put its money where its mouth is, agreeing to pay $40m up front to license worldwide rights to PRN2246, a Bruton’s tyrosine kinase (BTK) inhibitor just moved into clinical development by Principia BioPharma Inc. for multiple sclerosis.
While the upfront value is fairly low, Sanofi could also pay the San Francisco-area biotech milestones up to $765m and...








